Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenues	[1]	$ 12,028	$ 13,118
Earnings	[1],[2]	3,885	4,323
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		12,028	12,259
Earnings	[2]	7,920	8,162
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues		0	858
Earnings	[2]	(1,489)	(1,113)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Earnings	[2]	(812)	(1,038)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Earnings	[2]	(13)	(28)
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Revenues	[3]	0	0
Earnings	[2],[3]	(612)	(382)
Corporate and other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Earnings	[2]	(1,110)	(1,278)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues		10,007	9,045
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		10,007	9,045
Earnings	[2]	6,729	5,883
Upjohn [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		2,022	3,214
Earnings	[2]	$ 1,191	$ 2,279

[1] Amounts may not add due to rounding.

[2] Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4.

[3] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.